Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug cocktail tested for Tough-to-Treat blood cancer

NCT ID NCT01665794

Summary

This study tested a combination of three drugs—pomalidomide, dexamethasone, and carfilzomib—for people with multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to find a safe dose and see how well the combination worked to control the cancer. Treatment continued as long as it was helping and side effects were manageable.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • University Health Network - Princess Margaret Cancer Center

    Toronto, Ontario, MISG 2M9, Canada

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois, 60637-1470, United States

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan, 48109, United States

  • Wayne State University - Karmonos Cancer Center

    Detroit, Michigan, 48201, United States

Conditions

Explore the condition pages connected to this study.